ArticleFrontiers in oncology2025
Function value of basement membrane-related genes in odontogenic keratocyst by bioinformatics analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Odontogenic keratocyst (OKC) is an aggressive jaw lesion characterized by high recurrence rates. Disruption of the basement membrane (BM) may contribute to its pathogenesis, through the underlying molecular mechanisms remain incompletely understood. Methods: Transcriptomic data from 12 non-syndromic OKC and 4 normal oral mucosa (NOM) samples (GSE38494) were analyzed to identify differentially expressed BM-related genes (BM DEGs). Bioinformatics approaches included differential expression analysis, functional enrichment (Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Gene Set Enrichment Analysis), protein-protein interaction (PPI) network construction, immune infiltration assessment, and validation via single-cell RNA-seq (scRNA-seq; GSE176351). Key findings were confirmed immunohistochemistry and by immunofluorescence in clinical specimens. Results: A total of 65 BM DEGs were identified, with secreted protein acidic and cysteine rich (SPARC) being the most significantly upregulated gene (P < 0.01). PPI and correlation analyses established SPARC as a hub gene, showing significant correlation with recognized OKC markers (PTCH1, GLI1, GLI2, KRT19; P < 0.05). ScRNA-seq localized elevated SPARC expression predominantly to stromal fibroblasts. Immunohistochemistry and immunofluorescence confirmed significantly higher stromal SPARC expression in OKC versus NOM (P = 0.001). SPARC levels correlated with altered immune infiltration profiles, showing positive association with effector memory CD4+ T cells and negative association with memory B cells. Transcription factor and microRNA regulatory networks for SPARC were delineated. Conclusions: This study establishes dysregulation f BMGs-particularly stromal fibroblast-specific SPARC overexpression-as a contributor to OKC pathogenesis. SPARC interacts with key OKC pathways (Hedgehog, NOTCH) and modulates the immune microenvironment. These findings provide foundational insights into OKC aggressiveness and propose SPARC as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.